Renal impairment: A challenge for opioid treatment? The role of buprenorphine

Palliative Medicine

Volumn 20, Issue SUPPL. 1, 2006, Pages

  Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Active metabolite; Buprenorphine; Cockroft Gault formula; Creatinine clearance; Creatinine blind range; Elderly; Haemodialysis; Morphine; Renal impairment

Indexed keywords

BUPRENORPHINE; CODEINE; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FENTANYL; IBUPROFEN; MELOXICAM; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; DRUG METABOLITE; HYDROMORPHONE; OXYCODONE; TRAMADOL;

AGE DISTRIBUTION; APNEA; ARTICLE; CANCER PALLIATIVE THERAPY; CHRONIC KIDNEY FAILURE; CHRONIC PAIN; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE SEVERITY; DOSE KIDNEY FUNCTION RELATION; DOSE RESPONSE; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; REBOUND; RESPIRATION DEPRESSION; VULNERABLE POPULATION; AGE; AGED; COMORBIDITY; CONFERENCE PAPER; HEMODIALYSIS; KIDNEY FAILURE; KIDNEY FUNCTION TEST; LIVER METABOLISM; RENAL CLEARANCE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MIDDLE AGED; MORPHINE; MORPHINE DERIVATIVES; PAIN; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 33745042445     PISSN: 02692163     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997; 349: 1498-504.
2. Crook J, Rideout E, Browne G. The prevalence of pain complaints in a general population. Pain 1984; 18: 299-314.
3. Higginson I. Epidemiologically based needs assessment for palliative and terminal care. Radcliffe Medical Press, 1997.
4. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986; 80: 435-42.
5. Muhlberg W, Platt D. Age-dependent changes of the kidneys: pharmacological implications. Gerontology 1999; 45: 243-53.
6. Rowe JW, Andres R, Tobin JD, Norris AH, Shock NW. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 1976; 31: 155-63.
7. Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf 2001; 24: 19-38.
8. Canal P, Chatelut E, Guichard S. Practical treatment guide for dose individualisation in cancer chemotherapy. Drugs 1998; 56: 1019-38.
9. Wong NA, Jones HW. An analysis of discharge drug prescribing amongst elderly patients with renal impairment. Postgrad Med J 1998; 74: 420-22.
10. Mendelssohn DC, Barrett BJ, Brownscombe LM, et al. Elevated levels of serum creatinine: recommendations for management and referral. CMAJ 1999; 161: 413-17. Comment 1999; 161: 1237-38.
11. Platt D, Muhlberg W. Drug therapy for elderly patients [article in German]. Urologe A 1995; 34: 249-72.
12. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
13. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461-70.
14. Mercadante S. The role of morphine metabolites in cancer pain. Palliat Med 1999; 13: 95-104.
15. Peterson GM, Randall CT, Paterson J. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration. Eur J Clin Pharmacol 1990; 30: 121-24.
16. Chan GL, Matzke GR. Effects of renal insufficiency on the pharmacokinetics and pharmacodynamics of opioid analgesics. Drug Intell Clin Pharm 1987; 21: 773-83.
17. Bunn R, Ashley C. The renal drug handbook. Radcliffe Medical Press, 1999.
18. Mercadante S, Arcuri E. Opioids and renal function. J Pain 2004; 5: 2-19.
19. Angst MS, Buhrer M, Lotsch J. Insidious intoxication after morphine treatment in renal failure: delayed onset of morphine-6-glucuronide action. Anesthesiology 2000; 92: 1473-76.
20. Hand CW, Sear JW, Uppington J, Ball MJ, McQuay HJ, Moore RA. Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites. Br J Anaesth 1990; 64: 276-82.
21. Summerfield RJ, Allen MC, Moore RA, Sear JW, McQuay HJ. Buprenorphine in end-stage renal failure [Letter]. Anaesthesia 1985; 40: 914.
22. Ohtani M, Kotaki H, Nishitateno K, Sawada Y, Iga T. Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine. J Pharmacol Exp Ther 1997; 281: 428-33.
23. Mégarbane B, Marie N, Pirnay S, et al. Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation. Toxicol Appl Pharmacol 2005; epub ahead of print.
24. Dahan A, Yassen A, Bijl H, et al. Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 2005; 94: 825-34.
25. Filitz J, Griessinger N, Sittl R, Likar R, Schüttler J, Koppert W. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain, available online 19 January 2006. Epub ahead of print.
26. Stichtenoth DO, Wagner B, Frölich JC. Effects of meloxicam and indomethacin on cyclooxygenase pathways in healthy volunteers. J Investig Med 1997; 45: 44-48.